Recent Updates
Recently added Catalysts

EMBEDA

Phase 1

Nondependent Opioid Abuse, Episodic | Small molecule | Psychiatry |Pfizer, Inc.|Last Updated: May 31, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment80

FDA Designations

No designations recorded

Clinical trial landscape

EMBEDA · 1 trial · 1 indication

Phase 1 1
NCT01380093Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid UsersNondependent Opioid Abuse, Episodic
COMPLETED80 Analytics
PHASE1COMPLETED
Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
Nondependent Opioid Abuse, EpisodicUnlock trial analytics

Study Endpoints

Primary Endpoints

Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours
0.5, 1, 1.5 and 2 hrs post-dose

Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hours (hrs) (0-2).

Drug Liking: Peak Effect (Emax)
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose

Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm). Emax = Maximum observed score.

High: Area Under Effect Curve (AUE) From 0-2 Hours
0.5, 1, 1.5 and 2 hrs post-dose

High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hrs (0-2).

High: Peak Effect (Emax)
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose

High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.

Secondary Endpoints

Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour
0.5 and 1 hrs post-dose
Drug Liking: Area Under Effect Curve (AUE) From 0-4 Hours
0.5, 1, 1.5, 2, 3 and 4 hrs post-dose
Drug Liking: Area Under Effect Curve (AUE) From 0-8 Hours
0.5, 1, 1.5, 2, 3, 4, 6 and 8 hrs post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
PlaceboPLACEBO_COMPARATOR -
MS Contin (morphine sulfate, controlled release)ACTIVE_COMPARATOR -
EMBEDA (morphine sulfate / naltrexone hydrochloride)EXPERIMENTAL -

Interventions

NameTypeDescription
PlaceboDRUGSingle-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
MS Contin (morphine sulfate, controlled release)DRUGSingle-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
EMBEDA (morphine sulfate / naltrexone hydrochloride)DRUGSingle-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Subject is a recreational opioid user who is NOT physically dependent on opioids based on Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) criteria, and the Naloxone Challenge. A recreational opioid user is defined as recreationall...

Countries:United States
Unlock Eligibility Criteria